Compugen Ltd (CGEN) stock
CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.02−0.02 (-0.98%)
Close on Nov 17, 2026Market cap $191.00MP/E 5.3Yield –
Compugen price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Compugen's price to sales ratio was 2.7× on Nov 11, 2026, against 5.2× a year earlier. Over the last 5 years it ranged from 2.6× to 180.4×, with a median of 6.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.7× | −2.4 |
| 2025 | Dec 31, 2025 | 5.1× | +1.0 |
| 2024 | Dec 31, 2024 | 4.1× | −19.2 |
| 2023 | Dec 29, 2023 | 23.3× | +13.0 |
| 2022 | Dec 30, 2022 | 10.3× | −170.1 |
| 2021 | Dec 31, 2021 | 180.4× | +145.8 |
| 2020 | Feb 28, 2020 | 34.6× | +13.9 |
| 2019 | Dec 31, 2019 | 20.7× | −267.4 |
| 2018 | Feb 28, 2018 | 288.2× | +108.6 |
| 2017 | Dec 29, 2017 | 179.5× | +151.6 |
| 2016 | Dec 30, 2016 | 28.0× | +1.9 |
| 2015 | Dec 31, 2015 | 26.1× | −87.7 |
| 2014 | Dec 31, 2014 | 113.8× | −77.0 |
| 2012 | Feb 29, 2012 | 190.8× | +40.2 |
| 2011 | Dec 30, 2011 | 150.6× | −347.7 |
| 2010 | Nov 30, 2010 | 498.3× | – |
See a number that looks wrong?